Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX has made significant strides in commercialization, recording its first revenue from the CE-Marked Nu.Q NETs automated assay and expanding evaluations to over 20 hospitals across multiple countries and clinical indications. The company's strategic partnerships, specifically licensing agreements with established leaders like Werfen and Hologic, further elevate its credibility and market potential, signaling a robust human diagnostics licensing strategy. Additionally, VolitionRX's innovative and low-cost blood-based testing solutions, alongside advances in its Nucleosomics platform, position it favorably in a growing market focused on early disease detection and improved patient outcomes.

Bears say

VolitionRX Ltd faces increased dilution risk, leading to a reduction in their price target from $5.0 to $3.0, indicating potential challenges in achieving desired financial performance. This heightened risk may stem from the company’s ongoing need for capital to fund its research and development efforts, which could dilute existing shareholder value. Furthermore, the uncertainty surrounding the commercialization of its Nucleosomics platform and the broader market acceptance of its diagnostic tests contributes to a pessimistic financial outlook.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.